Kisqali Helps Treat Early-Stage Breast Cancer

episode

Breastcancer.org Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-22-2026 12PM EDT 5 min · 22 Sep 2026 · NPR News Now

Des Décisions Difficiles À Venir Pour Le Canadien | Le Sick Podcast Avec Tony Marinaro 22/09/26 1h 31m · 22 Sep 2026 · The Sick Podcast with Tony Marinaro / Le Sick Podcast avec Tony Marinaro

ep 399 | What does a Fed hiking cycle mean for markets? 8 min · 22 Sep 2026 · On Point

Ep. 2065 - How They Legally Killed An 83-Year-Old Grandmother 46 min · 22 Sep 2026 · The Michael Knowles Show

Why can’t we stop the DV crisis? 15 min · 22 Sep 2026 · ABC News Daily

The Friction Audit: Why You Need to Measure Pain, Not Just Profit 4 min · 22 Sep 2026 · The Level Up Podcast w/ Paul Alex

Report any issue

Source

Recorded07 Jun 2023

Publisherfeeds.megaphone.fm ↗

Handlerec:11088134

Show notes

At the 2023 American Society of Clinical Oncology Annual Meeting, Dr. Slamon presented results from the NATALEE trial, showing that Kisqali plus an aromatase inhibitor after surgery for early-stage, hormone receptor-positive, HER2-negative breast cancer, reduced recurrence risk by 25% compared to an aromatase inhibitor alone. Listen to the podcast to hear Dr. Slamon explain: why he thought Kisqali could benefit people with early-stage breast cancer the side effects Kisqali can cause what the results mean for people diagnosed with early-stage, hormone receptor-positive disease

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in